About Array BioPharma (NASDAQ:ARRY)
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ARRY
- CUSIP: 04269X10
- Web: www.arraybiopharma.com
- Market Cap: $2.16478 billion
- Outstanding Shares: 171,442,000
- 50 Day Moving Avg: $11.49
- 200 Day Moving Avg: $9.12
- 52 Week Range: $5.36 - $13.40
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -19.18
- P/E Growth: -1.15
- Annual Revenue: $43.66 million
- Price / Sales: 42.17
- Book Value: $0.07 per share
- Price / Book: 153.43
- EBITDA: ($100,010,000.00)
- Net Margins: -77.44%
- Return on Equity: -1,187.18%
- Return on Assets: -47.96%
- Debt-to-Equity Ratio: 11.42%
- Current Ratio: 3.88%
- Quick Ratio: 3.88%
- Average Volume: 4.12 million shs.
- Beta: 2.16
- Short Ratio: 8.62
Frequently Asked Questions for Array BioPharma (NASDAQ:ARRY)
What is Array BioPharma's stock symbol?
Array BioPharma trades on the NASDAQ under the ticker symbol "ARRY."
How were Array BioPharma's earnings last quarter?
Array BioPharma Inc. (NASDAQ:ARRY) released its earnings results on Wednesday, August, 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.04. The firm had revenue of $33.80 million for the quarter, compared to analyst estimates of $28.64 million. Array BioPharma had a negative return on equity of 1,187.18% and a negative net margin of 77.44%. Array BioPharma's revenue was down 21.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.17) earnings per share. View Array BioPharma's Earnings History.
When will Array BioPharma make its next earnings announcement?
Where is Array BioPharma's stock going? Where will Array BioPharma's stock price be in 2017?
7 analysts have issued 12 month target prices for Array BioPharma's stock. Their forecasts range from $9.00 to $18.00. On average, they anticipate Array BioPharma's stock price to reach $13.86 in the next year. View Analyst Ratings for Array BioPharma.
What are analysts saying about Array BioPharma stock?
Here are some recent quotes from research analysts about Array BioPharma stock:
- 1. Cantor Fitzgerald analysts commented, "ARRY’s e-poster presentation of the safety lead in for the Phase III BEACON CRC study suggests that binimetinib/encorafenib could expand its market potential to colorectal cancer, which the shares do not currently reflect, in our view." (9/8/2017)
- 2. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (8/11/2017)
- 3. Cowen and Company analysts commented, "We see ARRY's decision to withdraw the NRAS NDA as prudent given the known modest efficacy benefit. The NRAS-mutant melanoma opportunity represented a modest 6% of our base model DCF, thus we lower our PT modestly from $15 to $14. We view recent share weakness and the passing of this 'risk' event as an especially attractive opportunity to firmly reiterate our Outperform rating on ARRY shares." (3/20/2017)
Are investors shorting Array BioPharma?
Array BioPharma saw a drop in short interest in the month of September. As of September 29th, there was short interest totalling 23,385,574 shares, a drop of 18.6% from the September 15th total of 28,717,062 shares. Based on an average trading volume of 4,448,232 shares, the short-interest ratio is currently 5.3 days. Currently, 12.0% of the company's stock are short sold.
Who are some of Array BioPharma's key competitors?
Some companies that are related to Array BioPharma include Clovis Oncology (CLVS), BeiGene (BGNE), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), AveXis (AVXS), GW Pharmaceuticals PLC (GWPH), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Loxo Oncology (LOXO), Prothena Corporation PLC (PRTA), China Biologic Products (CBPO), Ultragenyx Pharmaceutical (RARE), Insmed (INSM), Intercept Pharmaceuticals (ICPT), NovoCure Limited (NVCR), Radius Health (RDUS) and AnaptysBio (ANAB).
Who are Array BioPharma's key executives?
Array BioPharma's management team includes the folowing people:
- Kyle A. Lefkoff, Independent Chairman of the Board
- Ron R. Squarer, Chief Executive Officer, Director
- Jason Haddock, Chief Financial Officer
- Andrew R. Robbins, Chief Operating Officer
- Nicholas A. Saccomano Ph.D., Chief Scientific Officer
- Curtis Oltmans, General Counsel
- Victor Sandor, Chief Medical Officer
- Shalini Sharp, Director
- Charles M. Baum M.D., Ph.D., Independent Director
- Gwendolyn A. Fyfe M.D., Independent Director
Who owns Array BioPharma stock?
Array BioPharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include
POINT72 ASSET MANAGEMENT, L.P.
(5.40%), Nationwide Fund Advisors (0.22%), Edge Wealth Management LLC (0.01%) and Fox Run Management L.L.C. (0.01%). Company insiders that own Array BioPharma stock include Charles M Baum, Kyle Lefkoff and Redmile Group, Llc. View Institutional Ownership Trends for Array BioPharma.
Who bought Array BioPharma stock? Who is buying Array BioPharma stock?
How do I buy Array BioPharma stock?
Shares of Array BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Array BioPharma's stock price today?
MarketBeat Community Rating for Array BioPharma (NASDAQ ARRY)MarketBeat's community ratings are surveys of what our community members think about Array BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Array BioPharma stock can currently be purchased for approximately $10.74.
Consensus Ratings for Array BioPharma (NASDAQ:ARRY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 6 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.86)|
|Consensus Price Target: ||$13.86 (29.02% upside)|Consensus Price Target History for Array BioPharma (NASDAQ:ARRY)
Analysts' Ratings History for Array BioPharma (NASDAQ:ARRY)
(Data available from 10/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/26/2017||Cantor Fitzgerald||Reiterated Rating||Buy||$15.00||High|
|9/20/2017||Piper Jaffray Companies||Reiterated Rating||Overweight||$14.00 -> $18.00||Low|
|9/12/2017||Jefferies Group LLC||Reiterated Rating||Buy||$9.00||Medium|
|9/11/2017||Cowen and Company||Reiterated Rating||Outperform||$14.00 -> $15.00||High|
|9/11/2017||Stifel Nicolaus||Reiterated Rating||Buy -> Buy||$13.00 -> $15.00||High|
|9/11/2017||J P Morgan Chase & Co||Reiterated Rating||Buy||$14.00||High|
|1/30/2017||Leerink Swann||Downgrade||Outperform -> Market Perform||$11.00||N/A|
|6/2/2016||SunTrust Banks, Inc.||Initiated Coverage||Buy||$7.00||N/A|
Earnings History for Array BioPharma (NASDAQ:ARRY)Earnings History by Quarter for Array BioPharma (NASDAQ ARRY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2017||Q4 2017||($0.21)||($0.17)||$28.64 million||$33.80 million||View||Listen|
|5/10/2017||Q3 2017||($0.16)||($0.21)||$38.28 million||$33.28 million||View||N/A|
|2/9/2017||Q2 2017||($0.18)||($0.14)||$31.90 million||$44.50 million||View||Listen|
|11/1/2016||Q117||($0.16)||($0.20)||$32.47 million||$39.30 million||View||Listen|
|8/4/2016||Q416||($0.14)||($0.17)||$41.51 million||$43.20 million||View||Listen|
|5/3/2016||Q316||($0.12)||($0.16)||$30.35 million||$43.00 million||View||Listen|
|2/2/2016||Q216||($0.06)||($0.17)||$32.70 million||$35.40 million||View||Listen|
|11/4/2015||Q116||($0.18)||($0.15)||$14.02 million||$16.20 million||View||Listen|
|8/3/2015||Q415||($0.16)||($0.09)||$10.29 million||$12.30 million||View||Listen|
|5/4/2015||Q315||($0.01)||$0.37||$6.00 million||$6.60 million||View||Listen|
|2/3/2015||Q215||($0.20)||($0.06)||$10.20 million||$26.92 million||View||Listen|
|11/4/2014||Q115||($0.22)||($0.21)||$6.35 million||$6.07 million||View||Listen|
|8/12/2014||Q414||($0.23)||($0.22)||$8.10 million||$6.00 million||View||Listen|
|4/29/2014||Q314||($0.21)||($0.20)||$9.40 million||$7.80 million||View||Listen|
|2/4/2014||Q214||($0.16)||($0.13)||$13.49 million||$14.10 million||View||Listen|
|10/31/2013||Q114||($0.18)||($0.13)||$11.20 million||$14.20 million||View||Listen|
|8/7/2013||Q4 2013||($0.13)||($0.06)||$16.13 million||$25.40 million||View||Listen|
|5/6/2013||Q3 2013||($0.14)||($0.19)||$14.54 million||$10.00 million||View||Listen|
|2/4/2013||Q2 2013||($0.14)||($0.10)||$16.52 million||$18.40 million||View||Listen|
|10/29/2012||Q113||($0.15)||($0.13)||$16.70 million||$15.80 million||View||N/A|
Earnings Estimates for Array BioPharma (NASDAQ:ARRY)
2017 EPS Consensus Estimate: ($0.94)
2018 EPS Consensus Estimate: ($1.01)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Array BioPharma (NASDAQ:ARRY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Array BioPharma (NASDAQ:ARRY)
Insider Ownership Percentage: 3.18%Insider Trades by Quarter for Array BioPharma (NASDAQ:ARRY)
Institutional Ownership Percentage: 85.77%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/29/2017||Kyle Lefkoff||Director||Sell||38,865||$12.31||$478,428.15|| |
|3/28/2017||Charles M Baum||Director||Sell||25,000||$9.27||$231,750.00|| |
|9/28/2016||Redmile Group, Llc||Major Shareholder||Sell||2,492,578||$6.36||$15,852,796.08|| |
|9/15/2016||Redmile Group, Llc||Major Shareholder||Buy||400,000||$3.51||$1,404,000.00|| |
|1/20/2016||Redmile Group, Llc||Major Shareholder||Buy||300,000||$3.19||$957,000.00|| |
|1/12/2016||Redmile Group, Llc||Major Shareholder||Buy||75,000||$3.60||$270,000.00|| |
|1/11/2016||Redmile Group, Llc||Major Shareholder||Buy||925,000||$3.67||$3,394,750.00|| |
|10/1/2015||Redmile Group, Llc||Major Shareholder||Buy||782,592||$4.58||$3,584,271.36|| |
|8/25/2015||Redmile Group, Llc||Major Shareholder||Buy||790,000||$5.38||$4,250,200.00|| |
|8/10/2015||Redmile Group, Llc||Major Shareholder||Buy||1,048,993||$5.80||$6,084,159.40|| |
|3/3/2015||Kyle Lefkoff||Director||Sell||70,000||$8.00||$560,000.00|| |
|3/2/2015||Andrews R Robbins||SVP||Sell||21,576||$8.25||$178,002.00|| |
|3/2/2015||Ron Squarer||CEO||Sell||40,000||$8.25||$330,000.00|| |
|9/16/2013||Liam Ratcliffe||Director||Sell||1,673,172||$6.08||$10,172,885.76|| |
|9/6/2013||Liam Ratcliffe||Director||Sell||577,286||$5.79||$3,342,485.94|| |
|8/2/2013||John R Moore||VP||Sell||75,384||$7.02||$529,195.68|| |
|7/23/2013||John R Moore||VP||Sell||5,000||$6.50||$32,500.00|| |
Headline Trends for Array BioPharma (NASDAQ:ARRY)
Latest Headlines for Array BioPharma (NASDAQ:ARRY)
Loading headlines, please wait.
Array BioPharma (ARRY) Chart for Tuesday, October, 24, 2017